There is growing awareness that B cells and alloantibodies are important mediators of both
acute and chronic allograft injury. Unfortunately, few therapies are clinically available to
mitigate the function of B cells or the effects of established alloantibody. As a result, many
sensitized people await transplantation without a suitable donor, and several rejection
syndromes are emerging that appear to involve B cells either as antibody producers or as
antigen-presenting cells. In recognition of this unmet need in transplantation, the American …